|
Modulating the AIBP-CAV1-VEGFR3 axis to treat lymphatic disorders
This invention is a method of promoting lymphangiogenesis in order to treat lymphatic disorders, namely lymphedema and Alzheimer’s disease (AD). VEGFC-induced VEGFR3 signaling is the major driver of lymphangiogenesis, however the distinct molecular mechanisms determining how VEGFR3 signaling controls lymphatic endothelial cell (LEC) fate remains...
Published: 3/12/2024
|
Inventor(s): Longhou Fang, Jun-dae Kim
Keywords(s):
Category(s): Clinical Area > Metabolic Disease, Inflammation, and Immunology, Clinical Area > Neurology, Clinical Area > Cardiovascular, Research Area > Heart and Vascular, Research Area > Immunobiology and Inflammation, Research Area > Neurology and Neurosurgery, Technology Classifications > Therapeutic > Cell and Gene Therapies, Technology Classifications > Therapeutic > Small Molecules, Technology Classifications > Therapeutic > Biologics
|
|
Aptamer-engineered Natural Killer Cells for Adaptive Immunotherapy
The invention is a unique technology to engineer Natural Killer (NK) cells with synthetic oligonucleotide aptamers for tumor cell-specific cancer immunotherapy. Stage of Development In vitro Study: The aptamer-engineered NK (ApEn-NK) cells could be generated via a simple one-step process in minutes. The generated ApEn-NK cells were able to specifically...
Published: 3/12/2024
|
Inventor(s): Youli Zu
Keywords(s):
Category(s): Clinical Area > Cancer, Research Area > Cancer, Clinical Area > Metabolic Disease, Inflammation, and Immunology, Technology Classifications > Therapeutic > Cell and Gene Therapies
|
|
Implantable therapeutic vaccine for the sustained long-term treatment and prevention of tumors and cancer (Nanolymph)
Description of InventionThe invention is a device consists of an immunostimulatory implant designed for the local recruitment and activation of immune cells against cancer. The system utilizes nanoporous membranes which allows for the sustained elution of immune adjuvants from transcutaneously refillable reservoirs embedded in the structure. With diffusion...
Published: 3/12/2024
|
Inventor(s): Alessandro Grattoni, Ying Chua
Keywords(s):
Category(s): Clinical Area > Cancer, Research Area > Cancer, Technology Classifications > Medical Device > Implantables, Technology Classifications > Therapeutic > Cell and Gene Therapies
|
|
A DNAzyme that targets the CAG repeat RNA in polyglutamine diseases
The invention is a synthetic single-stranded DNA molecule that functions as a specific RNA-cleaving DNA enzyme (or DNAzyme) as a potential therapeutic for the treatment of polyglutamine diseases. The binding arms of this synthetic DNAzyme are complementary to the CAG repeats found in the pathological expansion of CAG trinucleotide repeats in the translated...
Published: 3/12/2024
|
Inventor(s): Nan Zhang, Tetsuo Ashizawa
Keywords(s):
Category(s): Clinical Area > Neurology, Research Area > Neurology and Neurosurgery, Technology Classifications > Therapeutic > Cell and Gene Therapies
|
|
IRF4-Targeted Therapies for Cancer, Transplant Rejection, and Autoimmune Disorders
This invention is a method of depleting or over-expressing the transcription factor, interferon regulatory factor 4 (IRF4), in T cells as therapeutic strategy for conditions which are highly regulated by the immune system. The inventors have established that IRF4 represses PD-1, Helios, and other molecules associated with T cell function, representing...
Published: 4/15/2024
|
Inventor(s): Wenhao Chen, Xian Li
Keywords(s):
Category(s): Technology Classifications > Therapeutic > Cell and Gene Therapies, Clinical Area > Transplantation, Clinical Area > Cancer, Clinical Area > Metabolic Disease, Inflammation, and Immunology, Research Area > Cancer, Research Area > Immunobiology and Inflammation
|
|
SREBP2 Inhibitors for Treating T-Cell Acute Lymphoblastic Leukemia
This invention is a method of inhibiting sterol regulatory element-binding protein 2 (SREBP2) in order to treat, prevent, reverse, and/or ameliorate conditions associated with an improper number of hematopoietic stem and progenitor cells (HSPCs). SREBP22 is traditionally known as a transcription factor that plays a role in cholesterol homeostasis. However,...
Published: 3/12/2024
|
Inventor(s): Longhou Fang, Qilin Gu
Keywords(s):
Category(s): Technology Classifications > Therapeutic > Small Molecules, Technology Classifications > Therapeutic > Cell and Gene Therapies, Clinical Area > Cancer, Research Area > Cancer
|
|
PSMA-Targeted CAR-T Therapy for Castration-Resistant Prostate Cancer
This invention includes ten novel PSMA-targeted CAR-T therapies to treat castration-resistant prostate cancer. The CAR-T constructs were generated using scFvs from five different mouse hybridomas. We have further enhanced the lead PSMA-targeted CAR-T therapy by co-expressing IRF4 to regulate effector T cell activity and tissue infiltration. The co-expression...
Published: 3/12/2024
|
Inventor(s): Bin He
Keywords(s):
Category(s): Technology Classifications > Therapeutic > Biologics, Technology Classifications > Therapeutic > Cell and Gene Therapies, Clinical Area > Cancer, Research Area > Cancer
|
